Portfolio News

Staff Sgt. Robert Davis: Seeing is believing

Earlier this year Ms. Davis learned of the new technology entitled eSight’s glasses after a staff doctor demonstrated their use to her. The new Federal Drug Administration approved device is equipped with a high-speed, high definition camera that captures everything the user is looking at. eSight’s algorithms enhance the video feed and display it on two high-tech screens in front of the user’s eyes. Fill color video images are clearly seen by the user with visual clarity. The glasses help...
Read more...

Startups win another $500,000 from Boeing and CASIS for zero-gravity tech

Eleven startups in all have benefited from the “Technology in Space” prizes awarded since 2014 at MassChallenge Boston, with backing from CASIS and Boeing. The two startups selected for awards in 2015, Biorasis and LaunchPad Medical, should see their experiments fly to the space station next month aboard SpaceX’s Dragon cargo capsule. Read more >>
Read more...

Myomo Enters Canadian Market

Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a commercial stage medical robotics company, today announced that its Application for a Canadian Medical Device License has been approved by Health Canada. With the license, Myomo and its distribution partner, Ottobock, are now entering the Canadian market for commercial sale of the MyoPro myolelectric arm orthosis (powered brace). Read more >>
Read more...

Siamab Therapeutics Presents New PreClinical Safety Data

Siamab Therapeutics, Inc., a biopharmaceutical company developing novel cancer immunotherapies, today announced the presentation of new preclinical data demonstrating the safety of its novel anti-Sialyl-Tn (STn) antibody drug conjugates (ADCs) in multiple animal models, including non-human primates (NHPs). These results add to the company’s efficacy data findings showing that its anti-STn antibody therapeutics inhibit tumor progression in cell-line-derived and patient-derived xenograft (PDX) ovarian cancer and pancreatic cancer mouse models, with complete regression observed in some treatment arms. The preclinical efficacy...
Read more...